| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,675 |
1,469 |
$172K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,538 |
1,451 |
$148K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,353 |
1,320 |
$136K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
831 |
778 |
$88K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
709 |
684 |
$14K |
| 87428 |
|
251 |
248 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
598 |
262 |
$5K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,518 |
1,333 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
526 |
474 |
$3K |
| 81025 |
|
129 |
97 |
$189.75 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
19 |
19 |
$150.02 |
| 81003 |
|
259 |
194 |
$116.82 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
12 |
12 |
$75.00 |